Tag: rare-blood-disorders

As a gene‑editing therapy moves into its final phase trials, the medical community faces both unprecedented promise and complex ethical questions about the future of treating rare blood disorders.

As a pioneering CRISPR‑based therapy moves into its last clinical stage, the promise of a lasting cure for sickle cell disease and thalassemia confronts the realities of safety, cost, and…

As a CRISPR‑based therapy moves into the last stage of clinical testing, experts weigh the promise of a cure against the challenges of safety, cost, and equitable access.